jak inhibitors
| 3 min read
QDX and Prelude Therapeutics are developing drugs that selectively target the JAK2 V617F mutation, offering hope for patients with myeloproliferative neoplasms.
| 5 min read
Jeremy Gale leads Pfizer’s inflammation & immunology research program to develop new therapies for moderate to severe inflammatory bowel disease.
Page 1 of 1 - 2 Total Items
